Compare GOOD & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOOD | GALT |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.5M | 397.3M |
| IPO Year | 2003 | 2008 |
| Metric | GOOD | GALT |
|---|---|---|
| Price | $9.76 | $2.90 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $12.88 | N/A |
| AVG Volume (30 Days) | ★ 695.4K | 185.4K |
| Earning Date | 11-03-2026 | 11-16-2026 |
| Dividend Yield | ★ 12.40% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $161,336,000.00 | N/A |
| Revenue This Year | $5.86 | N/A |
| Revenue Next Year | $1.99 | N/A |
| P/E Ratio | $121.06 | ★ N/A |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $9.54 | $2.03 |
| 52 Week High | $13.28 | $7.13 |
| Indicator | GOOD | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 21.59 | 35.26 |
| Support Level | N/A | $2.78 |
| Resistance Level | $13.07 | $3.30 |
| Average True Range (ATR) | 0.34 | 0.30 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 9.90 | 5.13 |
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.